ACHE and Alzheimer disease: Some of the AChE inhibitor molecules currently being evaluated in clinical studies, such as memoquin targets different additional pathways of AD by exhibiting antioxidant functions, acting as β-secretase inhibitor, preventing Aβ aggregation and influencing tau hyperphosphorylation [15].